IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY);한양대학교 산학협력단
发明人:
SHIN, IN CHEOL,신인철,JU, JI HYUN,주지현,LEE, KYUNG MIN,이경민,YANG, WON SEOK,양원석
申请号：
KR1020110109939
公开号：
KR1020120055449A
申请日:
2011.10.26
申请国别(地区):
KR
年份:
2012
代理人:
摘要：
PURPOSE: A composition for anticancer including KRT19 antibody is provided to obstructing physical coupling between KRT19-HER2 by using KRT19 antibodies, thereby Preventing, reducing, and treating diseases related to the HER2 including breast cancer. CONSTITUTION: A composition for anticancer includes KRT19 antibody which complementarily unites with KRT19 protein as an active ingredient. The KRT19 consists of amino acid sequence which is represented by sequence number 1&lsqb；SEQ ID NO:1&rsqb；. The KRT19 antibody targets 78-330th sequences among the amino acid sequences represented by sequence number 1. The KRT19 antibody is a monoclonal antibody. The KRT19 antibody obstructs physical coupling between HER2 and KRT19.본 발명은 항 KRT19(Cytokerain19) 항체의 항암적 용도에 관한 것으로, 보다 구체적으로 KRT19-HER2 간의 상호작용 및 이와 관련된 분자적 메커니즘과 관련하여 KRT19(Cytokerain19)의 특정 부위를 타겟으로 하는 KRT19 항체를 이용한, HER2을 발현하는 암 치료 방법 및 항암제에 관한 것이다.
